EVIPLERA

This brand name is authorized in Austria, Cyprus, Estonia, Spain, Finland, France, Ireland, Israel, Lithuania, Netherlands, Poland, United Kingdom

Active ingredients

The drug EVIPLERA contains a combination of these active pharmaceutical ingredients (APIs):

1
UNII G70B4ETF4S - EMTRICITABINE
 

Emtricitabine is a synthetic nucleoside analogue of cytidine with activity that is specific to HIV-1, HIV-2 and HBV. Emtricitabine is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate, which competitively inhibits HIV-1 reverse transcriptase, resulting in DNA chain termination. Emtricitabine is a weak inhibitor of mammalian DNA polymerase α, β and ε and mitochondrial DNA polymerase γ.

 
Read more about Emtricitabine
2
UNII 212WAX8KDD - RILPIVIRINE HYDROCHLORIDE
 

Rilpivirine is a diarylpyrimidine NNRTI of HIV-1. Rilpivirine activity is mediated by non-competitive inhibition of HIV-1 reverse transcriptase (RT). Rilpivirine does not inhibit the human cellular DNA polymerases α, β and γ.

 
Read more about Rilpivirine
3
UNII OTT9J7900I - TENOFOVIR DISOPROXIL FUMARATE
 

Tenofovir disoproxil is absorbed and converted to the active substance tenofovir, which is a nucleoside monophosphate analogue. Tenofovir is then converted to the active metabolite, tenofovir diphosphate, an obligate chain terminator, by constitutively expressed cellular enzymes. Tenofovir diphosphate inhibits HIV-1 reverse transcriptase and the HBV polymerase by direct binding competition with the natural deoxyribonucleotide substrate and, after incorporation into DNA, by DNA chain termination.

 
Read more about Tenofovir disoproxil

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 EVIPLERA Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
J05AR08 Emtricitabine, tenofovir disoproxil and rilpivirine J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AR Antivirals for treatment of HIV infections, combinations
Discover more medicines within J05AR08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
EE Ravimiamet 1550731, 1550742
ES Centro de información online de medicamentos de la AEMPS 11737001
FI Lääkealan turvallisuus- ja kehittämiskeskus 441619
FR Base de données publique des médicaments 63578537
GB Medicines & Healthcare Products Regulatory Agency 205590
IL מִשְׂרַד הַבְּרִיאוּת 7167
LT Valstybinė vaistų kontrolės tarnyba 1063757, 1063758
NL Z-Index G-Standaard, PRK 146552
PL Rejestru Produktów Leczniczych 100087050

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.